BioCentury
ARTICLE | Company News

BioDelivery sales and marketing update

March 19, 2012 7:00 AM UTC

BioDelivery said the U.S. relaunch of pain drug Onsolis fentanyl is being postponed so that two appearance issues raised by FDA can be addressed. The agency noted the formation of microscopic crystals and a slight fading of the color during the product's 24-month shelf life after an inspection of the Aveva Drug Delivery Systems Inc. facility, where Onsolis is manufactured. Aveva is the contract manufacturer for Onsolis. ...